Medicare AdvantageCoverageMedium impact
MA08.085k, Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze®)
Independence Blue Cross·Oncology, Pharmacy·Pharmacy
Effective date
Apr 29, 2026
We identified it
Jun 19, 2026
Summary
This is a reissue of the existing policy MA08.085k covering Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze®), a specialty pharmaceutical agent used in oncology. The policy was reissued effective 04/29/2026 with a posted date of 04/29/2026. Without access to the full policy text content, specific coverage changes cannot be determined, but billing teams should review the reissued policy for any updates to coverage criteria, prior authorization requirements, or billing guidance.
Action Required
By 04/29/2026: Billing and clinical teams must review the full text of reissued policy MA08.085k at https://medpolicy.ibx.com/ibc/ma/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=04&FilterField2=MPSiteActivityLogYear&FilterValue2=2026#medicare-advantage-ma08-085k-asparaginase-erwinia-chrysanthe to identify any changes from the previous version. Determine if prior authorization requirements, covered indications, dosing limits, or billing codes have changed. Update billing system rules, prior authorization workflows, and provider communication as needed. Notify oncology providers of any coverage changes. Failure to implement changes may result in claim denials or improper billing.